In view of the aberrant Egr-1 or its signature gene expression seen in SSc and other forms of pathological fibrosis, these results suggest that sustained Egr-1 signaling could be implicated in SSc fibrogenesis, and blocking Egr-1 signaling pathway may be of therapeutic benefit in controlling the progression of fibrosis. This evidence concerns the gene EGR1 and systemic sclerosis.